<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862576/" ref="ordinalpos=2509&amp;ncbi_uid=5611039&amp;link_uid=PMC3862576" image-link="/pmc/articles/PMC3862576/figure/pone-0082236-g004/" class="imagepopup">Figure 4. Growth and survival <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span> activation is refractory to ROS1 inhibition in HCC78-TR cells..  From: Resistance to ROS1 Inhibition Mediated by EGFR <span class="highlight" style="background-color:">Pathway</span> Activation in Non-Small Cell Lung Cancer. </a></div><br /><div class="p4l_captionBody">Cells were treated with TAE684 (A) or crizotinib (B) for 4 hours. Lysates of the cells were then analyzed by Western blot using the indicated antibodies.</div></div>